Identification of 4-[4-(4-fluoro-phenyl)-thiazol-2-ylamino]-2,6-dimethyl- phenol (KR-33749) as an inhibitor of 5-lipoxygenase with potent antiinflammatory activity

Pharmacology

Volumn 86, Issue 2, 2010, Pages 65-72

  Cho, Young Sik ^a   Kim, Chi Hyun ^a   Surh, Ji Hee ^a   Kang, Nam Sook ^a   Yoo, Sung Eun ^a   Cheon, Hyae Gyeong ^a,b  

^a Korea Research Institute of Chemical Technology   (South Korea)

^b Gachon University College of Medicine   (South Korea)

Author keywords

5 Lipoxygenase inhibitor; Antiinflammatory activity; KR 33749

Indexed keywords

1 CHLORO 2,4 DINITROBENZENE; 4 [4 (4 FLUOROPHENYL)THIAZOL 2 YLAMINO] 2,6 DIMETHYLPHENOL; ANTIINFLAMMATORY AGENT; ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONIC ACID; ENZYME INHIBITOR; IMMUNOGLOBULIN E; KR 33749; LEUKOTRIENE B4; UNCLASSIFIED DRUG; ZILEUTON;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATOPIC DERMATITIS; BASOPHIL; CELL LYSATE; CONTROLLED STUDY; ENZYME ACTIVITY; IC 50; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; MALE; MOUSE; NONHUMAN; OTITIS; PRIORITY JOURNAL; RAT; SKINFOLD THICKNESS;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARACHIDONATE 5-LIPOXYGENASE; ARACHIDONIC ACID; CELL LINE, TUMOR; DERMATITIS, ATOPIC; DINITROCHLOROBENZENE; DOSE-RESPONSE RELATIONSHIP, DRUG; EDEMA; ISOENZYMES; LEUKOTRIENE B4; LIPOXYGENASE INHIBITORS; MALE; MICE; MICE, INBRED BALB C; OSMOLAR CONCENTRATION; RATS; RECOMBINANT PROTEINS; SKIN; SKIN DISEASES; THIAZOLES; TIME FACTORS; XYLENES;

EID: 77954557432     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000315488     Document Type: Article

References (29)

1. Funk CD: Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 2001; 294: 1871-1895.
2. Ford-Hutchinson AW, Bray MA, Doig MV, Shipley ME, Smith M.J.H.: Leukotriene B 4 , a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes. Nature 1980; 286: 264-265.
3. Piper PJ: Leukotrienes, potent mediators of airway constriction. Int Arch Allergy Immunol 1985; 76: 43-48.
4. Sampson AP: The leukotrienes: mediators of chronic inflammation in asthma. Clin Exp Allergy 1996; 45: 457-463.
5. van Deventer SJH: Small therapeutic molecules for the treatment of inflammatory bowel disease. Gut 2002; 50:iii47-iii53.
6. Brooks CDW, Summers JB: Modulators of leukotriene biosynthesis and receptor activation. J Med Chem 1996; 39: 2629-2654.
7. Wedi B, Kapp A: Pathophysiological role of leukotrienes in dermatological diseases: potential therapeutic implications. BioDrugs 2001; 15: 729-743.
8. Westcott JY, Smith HR, Wenzel SE, Larsen GL, Thomas RB, Felsien D, Voelkel NF: Urinary leukotriene E 4 in patients with asthma: effect of airways reactivity and sodium cromoglycate. Am Rev Respir Dis 1991; 143: 1322-1328.
9. Brain SD, Camp RD, Dowd PM, Black AK, Woollard PM, Mallet AI, Greaves MW: Psoriasis and leukotriene B 4 . Lancet 1982;ii:762-763.
10. Thorsen S, Fogh K, Broby-Johansen U, Søndergaard J: Leukotriene B 4 in atopic dermatitis: increased skin levels and altered sensitivity of peripheral blood T cells. Allergy 1990; 45: 457-463.
11. Drazen J: Clinical pharmacology of leukotriene receptor antagonists and 5-lipoxygenase inhibitors. Am J Respir Crit Care Med 1998; 157:S233-S237.
12. Israel E, Rubin P, Kemp JP, Grossman J, Pierson W, Siegel SC, Tinkelman D, Murray JJ, Busse W, Segal AT, Fish J, Kaiser HB, Ledford D, Wenzel S, Rosenthal R, Cohn J, Lanni C, Perlman H, Karahalios P, Drasen JM: The effect of inhibition of 5-lipoxygenase by zileuton in mild to moderate asthma. Ann Intern Med 1993; 118: 1059-1066.
13. Cho YS, Kim HS, Kim CH, Cheon HG: Application of the ferrous oxidation-xylenol orange assay for the screening of 5-lipoxygenase inhibitors. Anal Biochem 2006; 351: 62-68.
14. Waslidge NB, Hayes DJ: A colorimetric method for the determination of lipoxygenase activity suitable for use in a highthroughput assay format. Anal Biochem 1995; 231: 354-358.
15. Walther M, Holzhütter HG, Kuban RJ, Wiesner R, Rathmann J, Kühn H: The inhibition of mammalian 15-lipoxygenase by the anti-inflammatory drug ebselen: dual-type mechanism involving covalent linkage and alteration of the iron ligand sphere. Mol Pharmacol 1999; 56: 196-203.
16. Suzuki H, Ueda T, Juranek I, Yamamoto S, Katoh T, Node M, Suzuki T: Hinokitiol, a selective inhibitor of the platelet-type isozyme of arachidonic 12-lipoxygenase. Biochem Biophys Res Commun 2000; 275: 885-889.
17. Levine L: Inhibition of the A23187-stimulated leukotriene and prostaglandin biosynthesis of rat basophil leukemia (RBL-1) cells by nonsteroidal anti-inflammatory drugs, antioxidants, and calcium channel blockers. Biochem Pharmacol 1983; 32: 3023-3026.
18. Bradley PP, Priebat DA, Christensen RD, Rothstein G: Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J Invest Dermatol 1982; 78: 206-209.
19. Fogh K, Kragballe K: Eicosanoids in inflammatory skin diseases. Prostaglandins Other Lipid Mediat 2000; 63: 43-54.
20. Ruzicka T, Simmet T, Peskar BA, Ring J: Skin levels of arachidonic acid-derived inflammatory mediators and histamine in atopic dermatitis and psoriasis. J Invest Dermatol 1986; 86: 105-108.
21. Zhu YI, Stiller MJ: Preview of potential therapeutic applications of leukotriene B 4 inhibitors in dermatology. Skin Pharmacol Appl Skin Physiol 2000; 13: 235-245.
22. Ohnishi H, Miyahara N, Gelfand EW: The role of leukotriene B 4 in allergic diseases. Allergol Int 2008; 57: 291-298.
23. Lu P, Schrag ML, Slaughter DE, Raab CE, Shou M, Rodrigues D: Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. Drug Metab Dispos 2003; 31: 1352-1360.
24. Hammer RR, Tegeler JJ, Kurtz ES, Allen RC, Bailey SC, Elliott ME, Hellyer L, Helsley GC, Przekop P, Freed BS, White J, Martin LL: Dibenzoxepinone hydroxylamines and hydroxamic acids: dual inhibitors of cyclooxygenase and 5-lipoxygenase with potent topical antiinflammatory activity. J Med Chem 1996; 39: 246-252.
25. Dajani EZ, Islam K: Cardiovascular and gastrointestinal toxicity of selective cyclooxygenase-2 inhibitors in man. J Physiol Pharmacol 2008; 59(suppl 2):117-133.
26. Griswold DE, Webb E, Schwartz L, Hanna N: Arachidonic acid-induced inflammation: inhibition by dual inhibitor of arachidonic acid metabolism, SK&F 86002. Inflammation 1987; 11: 189-199.
27. Aioi A, Tonogaito H, Suto H, Hamada K, Ra C, Ogawa H, Maibach H, Matsuda H: Impairment of skin barrier function in NC/Nga Tnd mice as a possible model for atopic dermatitis. Br J Dermatol 2001; 144: 12-18.
28. Tomimori Y, Tanaka Y, Goto M, Fukuda Y: Repeated topical challenge with chemical antigen elicits sustained dermatitis in NC/ Nga mice in specific pathogen-free condition. J Invest Dermatol 2005; 124: 119-124.
29. Matsuda H, Watanabe N, Geba GP, Sperl J, Tsudzuki M, Hiroi J, Matsumoto M, Ushio H, Saito S, Askenase PW, Ra C: Development of atopic dermatitis-like skin lesion with IgE hyperproduction in NC/Nga mice. Int Immunol 1997; 9: 461-466.